Item 2. Unregistered Sales of Equity Securities
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
On August 8, 2025, we announced the annual renewal of our NCIB to purchase up to 12,855,691 of our common shares during the period of August 12, 2025 to August 11, 2026 or until such earlier time as the NCIB is completed or terminated at our option. The renewal followed the conclusion of our previous NCIB that expired August 11, 2025. Under the NCIB, we may make share repurchases on the TSX, the NYSE, the NYSE Texas, and/or alternative Canadian trading systems, at the prevailing market price at the time of the transaction and subject to certain volume limitations in accordance with the rules of the TSX and the SEC. The timing and amounts of any repurchases pursuant to the NCIB will depend on market conditions, share price and other factors, including potential acquisition growth opportunities. All common shares purchased under the NCIB will be immediately cancelled following their repurchase. During the six months ended June 30, 2026, we repurchased 3.8 million of our common shares pursuant to the NCIB in effect during that period at an aggregate cost of $614.5 million, or an average price of $163.53 per share. The table below reflects repurchases we made during the three months ended June 30, 2026:
Total Number of
Maximum Number
Shares Purchased
of Shares that
Total Number
Average
as Part of Publicly
May Yet Be
of Shares
Price Paid
Announced
Purchased Under
Period
Purchased
Per Share (a)
Program (b)
the Program (b)
4/1/26 - 4/30/26
541,205
$
165.35
541,205
9,160,001
5/1/26 - 5/31/26
453,691
$
156.42
453,691
8,706,310
6/1/26 - 6/30/26
1,067,750
$
159.30
1,067,750
7,638,560
2,062,646
$
160.25
2,062,646
(a) This amount represents the weighted average price paid per common share. This price includes a per share commission and buyback taxes paid for all repurchases.
(b) The annual renewal of our NCIB was announced on August 8, 2025, and unless terminated at our option, it will expire on August 11, 2026 or, if earlier, upon the purchase of the full 12,855,691 common shares authorized for purchase under the NCIB.
On July 21, 2026, our Board of Directors approved, subject to receipt of regulatory approvals, the annual renewal of our NCIB. The renewal is expected to commence following the conclusion of our current NCIB expiring August 11, 2026. Subject to receipt of regulatory approval, we anticipate that we will be authorized to make purchases during the period of August 12, 2026 to August 11, 2027 or until such earlier time as the NCIB is completed or terminated at our option.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.